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Abstract
Adequate detection of the production of carbapenemase in Enterobacteriaceae isolates is crucial for infection control
measures and the appropriate choice of antimicrobial therapy. In this study, we investigated the frequency of false
positive results for the detection of carbapenemases in carbapenemase-negative Escherichia coli and Klebsiella
pneumoniae clinical isolates by the modified Hodge test (MHT). Three hundred and one E. coli and K. pneumoniae
clinical isolates were investigated. All produced extended spectrum b-lactamases (ESBLs) but were susceptible to
carbapenems. Antimicrobial susceptibility testing was performed by the disk diffusion and agar dilution methods. The
MHT was performed using the standard inoculum of test organisms recommended by the CLSI. Genes that encoded ESBLs
and carbapenemases were identified by PCR and DNA sequencing. Among the 301 clinical isolates, none of the isolates
conformed to the criteria for carbapenemase screening recommended by the CLSI. The susceptibility rates for imipenem,
meropenem, and ertapenem all were 100.0%, 100.0%, and 100.0%, respectively. Of the 301 E. coli and K. pneumoniae
isolates, none produced carbapenemase. The MHT gave a positive result for 3.3% (10/301) of the isolates. False positive
results can occur when the MHT is used to detect carbapenemase in ESBL-producing isolates and clinical laboratories
must be aware of this fact.
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Introduction
The production of extended-spectrum b-lactamases (ESBLs) is
the most common mechanism of resistance to third-generation
cephalosporins in Enterobacteriaceae bacteria, especially Escherichia coli
and Klebsiella pneumoniae. Carbapenems are the drugs of last resort to
treat severe infections caused by pathogens that produce ESBLs [1–
2]. Although the rates of resistance to carbapenems are low, they
have been increasing [3]. During the past decade the spread of
antibiotic resistance in Enterobacteriaceae isolates, especially the
increase in K. pneumoniae carbapenemase (KPC)-producing isolates,
has become a major concern worldwide [4]. Infections due to KPC-
producing isolates have become an important challenge in
healthcare settings [5]. The rapid emergence of carbapenem-
resistant Enterobacteriaceae isolates in our hospital was revealed by
bacterial surveillance data. The rate of resistance to imipenem in K.
pneumoniae rose from 1.3% in 2006 to 11.1% in 2009, whereas the
rateinE.colirosefrom0.3%2006to1.0%in2009(datanotshown).
The production of carbapenemases, especially KPC-type
carbapenemases, is the most common mechanism for carbapenem
resistance in Enterobacteriaceae isolates [6–7]. However, the
detection of carbapenemases can be difficult because, for some
carbapenemase-producing Enterobacteriaceae, the minimum inhibi-
tory concentration (MIC) of carbapenem is high but still within the
susceptible range as defined by the Clinical and Laboratory
Standards Institute (CLSI) criteria [4,8–9]. In 2009, the CLSI
recommended the modified Hodge test (MHT) to screen for the
production of carbapenemase in Enterobacteriaceae isolates with
elevated MICs for carbapenems or reduced inhibition zones as
measured by disc diffusion. The criteria were a diameter for the
inhibition zones for meropenem and ertapenem of 19–21 mm and
16–21 mm, respectively, and MIC values of 2 mg/mL and 2–
4 mg/mL, respectively (carbapenem breakpoints have been
changed in M100-S20-U and M100-S21. According the new
criteria, the initial screen test and the confirmatory test by MHT
are no longer necessary for routine patient testing). Although the
sensitivity and specificity of the MHT have been shown to exceed
90%, several studies have reported false positive or false negative
results when this method was used to screen for carbapenemase in
Enterobacteriaceae isolates [8,10]. In this study, we investigated the
rate of false positives obtained when the MHT was used to test
ESBL-producing and carbapenemase-nagetive E. coli and K.
pneumoniae clinical isolates that did not conform to the CLSI
criteria for carbapenemase screening.
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Bacterial strains
Three hundred and one non-duplicate clinical isolates were
analysed. The isolates included 153 E. coli isolates and 148 K.
pneumoniae isolates and had been collected from January to
December 2008 in Huashan Hospital, Fudan University, Shang-
hai, China. All the isolates produced ESBLs, as confirmed by the
CLSI phenotypic confirmatory test initially, but were susceptible
to carbapenems (zones of inhibition of $19 mm in diameter for
ertapenem and $16 mm for meropenem, respectively) (9). As
control, 18 carbapenem-resistant, KPC-2 type carbapenemase-
producing K. pneumoniae clinical isolates were used in this study
(11).
Antimicrobial susceptibility testing and the MHT
Antimicrobial susceptibility testing was performed using agar
dilution methods recommended by the CLSI (9). Minimal
inhibitory concentrations (MICs) of cefazolin, cefoxitin, cefotax-
ime, ceftriaxone, aztreonam, ceftazidime, cefepime, ertapenem,
imipenem, meropenem, and piperacillin/tazobactam were deter-
mined in accordance with the CLSI criteria (9). The MHT was
carried out on all isolates to detect carbapenemase using
ertapenem and meropenem as described by the CLSI (9). A well
characterized strain of C. freundii that produced IMP-9-type
metallo-b-lactamase (MBL) and E. coli strain ATCC 25922 were
used as positive and negative controls, respectively.
Carbapenem inactivation assay
In order to determine whether resistance to imipenem and
meropenem was likely caused by production of carbapenemase, a
disk diffusion bioassay was performed on Mueller-Hinton agar
with imipenem, meropenem and ertapenem disks as described by
Yigit et al [12].
Genotypic detection of b-Lactamase
The b-lactamase genes TEM, SHV, PER, SFO, VEB, CTX-M
and GES, and carbapenemases including KPC, VIM, IPM, SPM,
SME, GIM, NMC, IMI, IND and OXA, were investigated in all of
clinical strains using previously described primers [13–15].
Conserved primers, forward primer KPC-F (59-AGGACTT-
TGGCGGCTCCAT-39) and reverse primer KPC-R (59-TCC-
CTCGAGCGCGAGTCTA-39), were designed against the KPC
gene to detect the KPC-1 to KPC-11 sequences according to the
published nucleotide sequences in Genbank, which encode dif-
ferent KPC-type carbapenemases and produced a 748-bp PCR
product. PCR amplicons were sequenced, and the DNA sequences
obtained were compared to the available sequences via National
Center for Biotechnology Information BLAST search.
Table 1. Antimicrobial activities of various antimicrobial
agents against 301 E. coli and K. pneumoniae isolates.
Drug MIC (mg/ml) S (%) R (%)
Range MIC50 MIC90
Imipenem #0.06–0.25 #0.06 #0.06 100.0 0.0
Meropenem #0.06–0.25 #0.06 #0.06 100.0 0.0
Ertapenem #0.06–0.25 #0.06 0.125 100.0 0.0
Cefepime 0.125–.128 16 64 30.9 48.2
Ceftazidime 0.25–.128 32 .128 27.9 62.1
Cefotaxime 0.125–.128 128 .128 0.3 99.7
Ceftriaxone 0.125–.128 .128 .128 0.3 99.7
Cefoxitin 1–.128 8 128 62.8 19.9
Cefazolin 128–.128 .128 .128 0.0 100.0
Piperacillin-tazobactam 0.5–.128 8 .128 65.8 23.9
Aztreonam 0.25–.128 64 .128 8.6 83.1
doi:10.1371/journal.pone.0026356.t001
Figure 1. False-positive result on MHT. A, K2821 K. pneumoniae
(KPC-2 carbapenemase producer). B, 08-438 E.coli.C ,0 8 - 9 7K.
pneumoniae.D ,E. coli ATCC 25922.
doi:10.1371/journal.pone.0026356.g001
Table 2. Distribution of ESBL genes among the 301 E. coli and K. pneumoniae isolates.
ESBL genes Genotype Number %
SVH-type ESBLs SHV-2, SHV-12, SHV-28, SHV-31 8 2.7
CTX-M-type ESBLs CTX-M-14, CTX-M-15, CTX-M-25 243* 80.7
TEM + CTX-type ESBLs TEM-40, TEM-135, CTX-M-14, CTX-M-15 3 1.0
SHV + CTX-M-type ESBLs SHV-2, SHV-12, SHV-28, SHV-31, CTX-M-14, CTX-M-15, CTX-M-25 34 11.3
Negative** 13 4.3
Total 301 100.0
*: 9.0% (22/243) isolates were producing both CTX-M-14 and CTX-M-15 type ESBL, and 1.2% (3/243) isolates were producing both CTX-M-14 and CTX-M-25 type ESBL.
**: We did not detected the TEM, SHV or CTX-M type ESBLs among these isolates.
doi:10.1371/journal.pone.0026356.t002
False Positive Result for Detecting Carbapenemases
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The outer membrane proteins of all isolates with false-positive
result on MHT were examined by sodium dodecyl sulfate
polyacrylamide gel electrophoresis, as described previously [14].
Ethics Statement
As this study was focused on bacterial isolates collected from
routine samples, approval from ethics committee at Fudan
University was not necessary. Neither was there any need for
informed consent procedures as no extra sampling was performed
and no personal data was stored in relation to the isolates.
Results
Antimicrobial susceptibility testing
The results of the antimicrobial susceptibility testing indicated
that, for the 301 isolates tested, the inhibition zones for meropenem
and ertapenem all had a diameter greater than 22 mm, and the
MICvalueswereall below1 mg/mL.Therefore,none ofthe isolates
conformed to the CLSI criteria for carbapenemase screening
(namely, diameters for meropenem and ertapenem of 19–21 mm
and 16–21 mm, respectively, and MIC values of 2 mg/mL and 2–
4 mg/mL, respectively.). None of the isolates was found to be
susceptible to cefazolin and 99.7%, 62.1%, 48.2%, and 19.9% were
resistant to cefotaxime, ceftazidime, cefepime, and cefoxitin,
respectively. The susceptibility rates for imipenem, meropenem,
and ertapenem were 100.0%, 100.0%, and 100.0%, respectively
(Table 1).
PCR amplification of b-lactamase genes and the MHT
Of the 301 E. coli and K. pneumoniae isolates, none produced
carbapenemase. Genes that encoded the CTX-M-type ESBLs
were detected in 280 (93.0%) of the isolates, among which CTX-
M-14, CTX-M-15, CTX-M-25, CTX-M-14 coupled with CTX-
M-15, and CTX-M-14 coupled with CTX-M-25 type ESBL were
found in 135 (48.2%), 112 (40.0%), 2 (0.7%), 28 (10.0%), and 3
(1.1%) of the isolates, respectively. Among 301 isolates, 18.3%
were producing more than two types of ESBLs, such as TEM-type
and CTX-M-type ESBLs, SHV-type and CTX-M-type ESBLs
(Table 2). Although all the isolates were sensitive to carbapenems
and carbapenemase-negative, the MHT yielded a positive result
(Figure 1) for 3.3% (10/301) of the isolates and all the MHT-
positive isolates (except one isolate was SHV-12 type ESBL
producer) were CTX-M type ESBL producing (Table 3). Among
18 carbapenem-resistant K. pneumoniae clinical isolates, all were
produced KPC-2 type carbapenemase and all were producing a
positive result of MHT.
Carbapenem inactivation assay
A carbapenem inactivation assay performed on all 301
carbapenems-susceptible isolates indicated that alterations in
shape of the zones of inhibition around the test organism were
not observed, suggesting no carbapenemase was involved in
hydrolysis of carbapenems in these isolates. However The assay of
all 18 KPC-2 type carbapenemase-producing K. pneumoniae isolates
were positive.
Analysis of outer membrane proteins
Analysis of the outer membrane porin proteins by sodium
dodecyl sulfate polyacrylamide gel electrophoresis showed that all
10 isolates (except 08-438 E.coli) exhibited loss of one of porin
protein compared with the sensitive strains (Figure 2 and Figure 3).
This suggests that the outer membrane porin proteins might play
an important role in resulting to the false-positive result.
Table 3. The characteristics of the 10 false-positive isolates by MHT.
Number Organism MIC (mg/L) ESBLs genes
Cefotaxime Ceftazidime Cefoxitin Ertapenem
08-309 E. coli 128 2 4 #0.06 CTX-M-14
08-318 E. coli .128 128 8 #0.06 CTX-M-15
08-438 E. coli 128 32 .128 #0.06 CTX-M-15
08-547 E. coli 64 4 16 #0.06 CTX-M-14
08-1002 E. coli 128 16 8 #0.06 CTX-M-15
08-1039 E. coli 128 2 4 #0.06 CTX-M-14
08-97 K. pneumoniae .128 .128 4 #0.06 CTX-M-15, SHV-28
08-1105 K. pneumoniae .128 128 4 #0.06 CTX-M-15
08-466 K. pneumoniae 64 .128 128 0.125 SHV-12
08-893 K. pneumoniae .128 128 4 #0.06 CTX-M-15, SHV-61
doi:10.1371/journal.pone.0026356.t003
Figure 2. 1. E.coli ATCC 25922, 2. 08-309 E.coli, 3. 08-318 E.coli,
4. 08-438 E.coli,5 .E.coli ATCC 25922, 6. 08-547 E.coli, 7. 08-1002
E.coli, 8. 08-1039 E.coli, M. Marker.
doi:10.1371/journal.pone.0026356.g002
False Positive Result for Detecting Carbapenemases
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Given the increasing prevalence of carbapenemase-producing
Enterobacteriaceae isolates worldwide [4], simple and accurate tests
are needed to detect isolates that produce carbapenemase. For this
purpose, the CLSI have recommended the MHT for the detection
of carbapenemase in Enterobacteriaceae isolates. Although the MHT
is a simple method for detecting carbapenemase-positive isolates,
false positive results are obtained occasionally [8,10]. In June
2010, CLSI changed the carbapenem breakpoints and reviewed
the recommendation on carbapenemase detection by MHT
among Enterobacteriacea (M100-S20-U) and informed that MHT
would not be recommended, except for epidemiological or
infection control purposes.. In this study, we used carbapenem-
susceptible E. coli and K. pneumoniae isolates that did not conform to
the CLSI criteria for screening for the presence of carbapenemase.
False positive results for the MHT were obtained among 3.3% of
the isolates. We presume that the false positive results are probably
due to low-level hydrolysis of ertapenem by ESBLs, particularly
those of the CTX-M type, because we found that 97.3% of the
isolates in our study produced CTX-M-type ESBLs [10,16].
Although the false positive results were observed in our study,
MHT is not recommended (and never was) to detect carbapene-
mase among isolates that yielded negative-result on screening test.
Whether for epidemiological or infection control purposes,
adequate detection of the production of carbapenemase in
Enterobacteriaceae isolates is crucial for infection control measures
and the appropriate choice of antimicrobial therapy [8]. To
improve the detection of carbapenemase-producing Enterobacteria-
ceae in clinical microbiology laboratories, several phenotypic tests
to detect KPCs have been developed [17–20]. In addition to the
MHT, a second phenotypic method has been shown to be
promising for the identification of KPCs. This method utilizes
boronic acid and 3-aminophenyl boronic acid-based compounds,
and has proved to be highly sensitive and specific for the detection
of KPCs.
In summary, as reported, CTX-M-type ESBLs might be
hydrolysing the ertapenem used in the assay [16]. Clinical
laboratories must be aware that false positive results may occur,
especially in geographical areas where the incidence of isolates that
produce CTX-M-type ESBLs is relatively high, such as the Asia-
Pacific region [21]. Hence, further work is necessary to determine
the frequency of false positive results when the MHT is used to
detect carbapenemase production in Enterobacteriaceae isolates and
more accurate methods should be developed for use in clinical
microbiology laboratories.
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